TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03592485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane blockade
Description: Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane blockade
Description: Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Fascia block
Description: Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
Study: NCT04011514

Intervention type: BEHAVIORAL
Intervention: Dedicated stroke nurse care in ED
Description: A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit

Intervention type: BEHAVIORAL
Intervention: Dedicated stroke nurse care in ED
Description: A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
Study: NCT03592485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted
Study: NCT02275169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urofollitropin
Description: Urofollitropin 75 IU 2 ampoules three times a week for three months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ampoules administered three times a week for three months
Study: NCT06275438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The delivery being performed via cesarean section surgery rather than natural childbirth
Description: At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
Study: NCT03592485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Each patient will generally anesthetized and endotracheal tube will be inserted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Paracetamol will be given i.v. every 6 hours.
Study: NCT01836302

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT03112655

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RNA and neopterin detection
Description: Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin and 5-hydroxytryptophan will be quantified in cerebrospinal fluid taken at the same time points.
Study: NCT02120391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPhone Application
Description: All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: iPhone Application
Description: All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
Study: NCT04467281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-daratumumab
Description: Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients will undergo 89Zr-DFO-daratumumab PET/CT once before standard of care therapy and once again afterward, for a total of two research scans.
Study: NCT02120326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation of the motor cortex
Description: The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* 2 mA intensity~* Continuous stimulation for 20 min with rise times and fall times of 10 seconds each
Study: NCT03724318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of the left atrium appendage
Description: closure of the left atrium appendage in addition to the planned Heart operation
Study: NCT01277757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given orally (PO) weekly, starting (dose 0) at 200 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00556088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589, Paclitaxel, Carboplatin, Bevacizumab
Description: LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.
Study: NCT02432027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C-82 Topical Gel, Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-82 Topical Gel, 1%
Description: active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivonex cream
Description: comparator
Study: NCT02120326

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: simulation of Transcranial direct current stimulation of the motor cortex
Description: The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~* The intensity of the stimulation current is 2 mA~* The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation.
Study: NCT02489383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Exercise Training
Description: The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval Exercise Training
Description: The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
Study: NCT02432027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosis gel
Description: comparator
Study: NCT01733394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand
Study: NCT02489383

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
Study: NCT02153580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT02153580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT02139488

Intervention type: OTHER
Intervention: Fiducial markers

Intervention type: OTHER
Intervention: Fiducial markers, Pet and MRI
Description: Insertion of Fiducial markers in esophageal wall.
Study: NCT02059304

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of cervical length with embryo transfer catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of cervical length with embryo transfer catheter
Study: NCT01934010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection
Study: NCT01497301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Visits
Description: During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants.
Study: NCT03515096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhTPO
Description: rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
Study: NCT01733394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Study: NCT02874755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculosis Program
Description: The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
Study: NCT01620814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control
Study: NCT03369769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity
Description: 10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity
Description: 10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
Study: NCT01095302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMBRABULIN (AVE8062)
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study: NCT01620814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control
Study: NCT01095302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion
Study: NCT03719911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live diabetes coaching program
Description: Live diabetes coaching program
Study: NCT01035281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone, flexible dosing
Description: nabilone at 0.5 - 4 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nabilone, flexible dosing
Description: nabilone at 0.5 - 4 mg/day
Study: NCT00410007

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Sodium Diet
Description: 250-350 mmol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Sodium Diet
Description: 250-350 mmol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Sodium Diet
Description: 25-35 mmol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Sodium Diet
Description: 25-35 mmol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: 7 ml/ kg of 3% saline were given over 30 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: 7 ml/ kg of 3% saline were given over 30 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: 7 ml/ kg of 3% saline were given over 30 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertonic saline infusion
Description: 7 ml/ kg of 3% saline were given over 30 minutes.
Study: NCT04102072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg Maneuver
Description: In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
Study: NCT01559142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab with azathioprine (IIFX + AZA)
Description: Infliximab with azathioprine during whole one year study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (IFX alone)
Description: Infliximab continuously; azathioprine stopped in 26 week
Study: NCT03554798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2 (monovalent oral polio vaccine)
Description: Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2 (monovalent oral polio vaccine)
Description: Cohort A: 150 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~Cohort B: 972 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2.
Study: NCT03487562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Amg
Description: DWP14012 Amg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Bmg
Description: DWP14012 Bmg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 500 mg
Study: NCT00408525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
Study: NCT04102072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dobutamine stress test
Description: Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
Study: NCT01947751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVC exchange
Description: CVC exchange when related infection is suspected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC maintenance
Description: CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
Study: NCT03745079

Intervention type: OTHER
Intervention: Esophagus temperature monitoring
Description: Measuring core temperature by esophageal stethoscope

Intervention type: OTHER
Intervention: Spoton Temporal
Description: Mesuring temperature on skin near to temporal artery using Spoton

Intervention type: OTHER
Intervention: Spoton Carotid
Description: Mesuring temperature on skin near to carotidl artery using Spoton
Study: NCT03815461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
Study: NCT02732834

Intervention type: BEHAVIORAL
Intervention: 2-hour empathic communication skills training
Description: 2-hour empathic communication skills training

Intervention type: BEHAVIORAL
Intervention: Standardized Patient Assessments
Description: pre-training SPA, post-training SPA

Intervention type: BEHAVIORAL
Intervention: Training evaluation
Description: Clinicians will complete an evaluation assessing the empathic communication training module.
Study: NCT02278861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral isotretinoin
Description: Oral isotretinoin - 10mg/day (one pill) after lunch for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin 0,05% cream
Description: Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen FPS 60
Description: Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
Study: NCT04060056

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized breakfast
Description: Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
Study: NCT02278861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen FPS 60
Description: Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
Study: NCT04060056

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized snack
Description: Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized lunch
Description: Participants will be provided with a standardized lunch 2 h after they have the standardized snack.